Tofacitinib for the treatment of alopecia areata and variants in adolescents

详细信息    查看全文

• 作者：Brittany G. Craiglow ; MD^a ; ^b ; ^{brittany.craiglow@yale.edu} ; Lucy Y. Liu ; BA^c ; Brett A. King ; MD ; PhD^a
• 关键词：adolescent ; alopecia areata ; Janus kinase ; tofacitinib
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：76
• 期：1
• 页码：29-32
• 全文大小：297 K
• 卷排序：76

文摘

There are no reliably effective therapies for alopecia areata (AA).ObjectiveWe sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of adolescent patients with AA.MethodsWe reviewed the records of 13 adolescent patients with AA treated with tofacitinib. Severity of disease was assessed using the Severity of Alopecia Tool (SALT). Adverse events were evaluated by laboratory monitoring, physical examinations, and review of systems.ResultsThirteen patients, aged 12 to 17 years, with AA were treated with tofacitinib. Nine patients experienced clinically significant hair regrowth. Median percent change in SALT score was 93% (mean 61%; 1%-100%) at an average of 6.5 months of treatment. Adverse events were mild.LimitationsLimitations include the retrospective nature of the data, small sample size, and lack of a control group.ConclusionTofacitinib is a promising therapy for AA in adolescents. The use of tofacitinib and other Janus kinase inhibitors for the treatment of AA in this age group should be further evaluated in prospective clinical trials.